We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The Office of the US Trade Representative (USTR) has opted to maintain
India's "priority watch" status on intellectual property compliance,
despite the country's recent approval of a much tougher patent law.
State-owned pharmaceutical company PT Bio Farma said it may reduce exports of
polio vaccines to guarantee local supplies following the discovery of polio
cases in Sukabumi.
Atugen AG announced that it has achieved nine of its milestones under its target
validation research contract with Schering AG and its U.S.-based subsidiary,
Berlex Biosciences.
The ministry of commerce has asked the Basic Chemicals, Pharmaceuticals &
Cosmetics Export Promotion Council (Chemexcil) to wind up its pharma panel and
stop all export promotion activities related to drugs and pharmaceuticals.
Oxford BioMedica, the leading gene therapy company, announced that the European
Patent Office has granted a key patent (No. EP1036091), that provides broad
protection for Oxford BioMedica's lead product, TroVax.
The Ministry of Health is considering extending the
protection period for new drugs to eight years from the current six in order
to give pharmaceutical firms a better opportunity to recoup development costs
and secure profits, the Nihon Keizai Shimbun reported over the weekend.
Following South African drug regulators' refusal to issue binding
advice on the efficacy of controversial vitamin-based "medicines"
for HIV/AIDS, health minister Manto Tshabalala-Msimang has defended the products.
A new study of Latin America's drug market prepared by PricewaterhouseCoopers
claims that Latin America's drug market holds sizeable "untapped potential"
for both R&D and innovative drugs.
Germany's Statutory Health Insurance (SHI) Modernisation Act, introduced
in January 2004 in the wake of the country's wider economic and welfare reform
drive, remains the focus of criticism from all sides of debate.